{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:53:50Z","timestamp":1793462030040,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2007,7,25]],"date-time":"2007-07-25T00:00:00Z","timestamp":1185321600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2007,12,6]]},"DOI":"10.1007\/s00432-007-0278-x","type":"journal-article","created":{"date-parts":[[2007,7,24]],"date-time":"2007-07-24T03:25:13Z","timestamp":1185247513000},"page":"245-253","source":"Crossref","is-referenced-by-count":54,"title":["Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways"],"prefix":"10.1007","volume":"134","author":[{"given":"Leander","family":"Gaul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Mandl-Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertold","family":"Emmerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Schmidmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,7,25]]},"reference":[{"key":"278_CR1","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1101\/gad.914401","volume":"15","author":"RT Abraham","year":"2001","unstructured":"Abraham RT (2001) Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 15:2177\u20132196","journal-title":"Genes Dev"},{"key":"278_CR2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.yexcr.2004.08.035","volume":"302","author":"J Agner","year":"2005","unstructured":"Agner J, Falck J, Lukas J, Bartek J (2005) Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway. Exp Cell Res 302:162\u2013169","journal-title":"Exp Cell Res"},{"key":"278_CR3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF et al (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335:91\u201397","journal-title":"N Engl J Med"},{"key":"278_CR4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.canlet.2006.03.032","volume":"247","author":"AM Bode","year":"2006","unstructured":"Bode AM, Dong Z (2006) The enigmatic effects of caffeine in cell cycle and cancer. Cancer Lett 247:26\u201339","journal-title":"Cancer Lett"},{"key":"278_CR5","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1158\/1535-7163.MCT-05-0138","volume":"4","author":"P Bozko","year":"2005","unstructured":"Bozko P, Sabisz M, Larsen AK, Skladanowski A (2005) Cross-talk between DNA damage and cell survival checkpoints during G2 and mitosis: pharmacologic implications. Mol Cancer Ther 4:2016\u20132025","journal-title":"Mol Cancer Ther"},{"key":"278_CR6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/35075107","volume":"411","author":"DV Bulavin","year":"2001","unstructured":"Bulavin DV, Higashimoto Y, Popoff IJ, Gaarde WA, Basrur V, Potapova O et al (2001) Initiation of a G2\/M checkpoint after ultraviolet radiation requires P38 kinase. Nature 411:102\u2013107","journal-title":"Nature"},{"key":"278_CR7","doi-asserted-by":"crossref","first-page":"7691","DOI":"10.1038\/sj.onc.1207986","volume":"23","author":"G Buscemi","year":"2004","unstructured":"Buscemi G, Perego P, Carenini N, Nakanishi M, Chessa L, Chen J et al (2004) Activation of ATM and Chk2 kinases in relation to the amount of DNA strand breaks. Oncogene 23:7691\u20137700","journal-title":"Oncogene"},{"key":"278_CR8","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1038\/sj.onc.1207394","volume":"23","author":"L Busino","year":"2004","unstructured":"Busino L, Chiesa M, Draetta GF, Donzelli M (2004) Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis. Oncogene 23:2050\u20132056","journal-title":"Oncogene"},{"key":"278_CR9","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1126\/science.281.5383.1677","volume":"281","author":"CE Canman","year":"1998","unstructured":"Canman CE, Lim DS, Cimprich KA, Taya Y, Tamai K, Sakaguchi K et al (1998) Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281:1677\u20131679","journal-title":"Science"},{"key":"278_CR10","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1038\/sj.onc.1202925","volume":"18","author":"P Chaturvedi","year":"1999","unstructured":"Chaturvedi P, Eng WK, Zhu Y, Mattern MR, Mishra R, Hurle MR et al (1999) Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 18:4047\u20134054","journal-title":"Oncogene"},{"key":"278_CR11","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","volume":"348","author":"JA Child","year":"2003","unstructured":"Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al (2003) Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875\u20131883","journal-title":"N Engl J Med"},{"key":"278_CR12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4161\/cc.3.1.631","volume":"3","author":"G Damia","year":"2004","unstructured":"Damia G, Broggini M (2004) Cell cycle checkpoint proteins and cellular response to treatment by anticancer agents. Cell cycle 3:46\u201350","journal-title":"Cell cycle"},{"key":"278_CR13","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/35071124","volume":"410","author":"J Falk","year":"2001","unstructured":"Falk J, Mailand N, Syljuasen RG, Bartek J, Lukas J (2001) The ATM-Chk2-cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410:842\u2013847","journal-title":"Nature"},{"key":"278_CR14","doi-asserted-by":"crossref","first-page":"8089","DOI":"10.1038\/sj.onc.1206000","volume":"21","author":"AP Garner","year":"2002","unstructured":"Garner AP, Weston CR, Todd DE, Balmanno K, Cook SJ (2002) Delta MEKK3:ER* activation induces a p38 alpha\/beta 2-dependent cell cycle arrest at the G2 checkpoint. Oncogene 21:8089\u20138104","journal-title":"Oncogene"},{"key":"278_CR15","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/00001813-200110000-00003","volume":"12","author":"A Heider","year":"2001","unstructured":"Heider A, Niederle N (2001) Efficacy and toxicity of bendamustine in patients with relapsed low-grade Non Hodgkin\u2019s lymphomas. Anticancer Drugs 12:725\u2013729","journal-title":"Anticancer Drugs"},{"key":"278_CR16","doi-asserted-by":"crossref","unstructured":"Herold M, Schulze A, Niederwieser D, Franke A, Fricke HJ, Richter P et al. for the East German Study Group Hematology and Oncology (OSHO) (2006). Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin`s lymphoma and mantle cell lymphoma: results of a randomised phase 3 trial (OSHO# 19). J Cancer Res Clin Oncol 132:105\u2013112","DOI":"10.1007\/s00432-005-0023-2"},{"key":"278_CR17","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/blood-2002-06-1874","volume":"101","author":"T Hideshima","year":"2003","unstructured":"Hideshima T, Akiyama M, Hayashi T, Richardson P, Schlossman R, Chauhan D et al (2003) Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood 101:703\u2013705","journal-title":"Blood"},{"key":"278_CR18","doi-asserted-by":"crossref","first-page":"8766","DOI":"10.1038\/sj.onc.1208118","volume":"23","author":"T Hideshima","year":"2004","unstructured":"Hideshima T, Podar K, Chauhan D, Ishitsuka K, Mitsiades C, Tai YT et al (2004) P38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 23:8766\u20138776","journal-title":"Oncogene"},{"key":"278_CR19","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1126\/science.287.5459.1824","volume":"287","author":"A Hirao","year":"2000","unstructured":"Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H et al (2000) DNA-damage induced activation o P53 by the checkpoint kinase Chk2. Science 287:1824\u20131827","journal-title":"Science"},{"key":"278_CR20","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s004320050225","volume":"124","author":"K Hoffken","year":"1998","unstructured":"Hoffken K, Merkle K, Schonfelder M, Anger G, Brandtner M, Ridwelski K, Seeber S (1998) Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study. J Cancer Res Clin Oncol 124:627\u2013632","journal-title":"J Cancer Res Clin Oncol"},{"key":"278_CR21","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s004320000180","volume":"127","author":"R Kath","year":"2001","unstructured":"Kath R, Blumenstengel K, Fricke HJ, Hoffken K (2001) Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 127:48\u201354","journal-title":"J Cancer Res Clin Oncol"},{"key":"278_CR22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00432-002-0331-8","volume":"128","author":"SM Konstantinov","year":"2002","unstructured":"Konstantinov SM, Kostovski A, Topashka-Ancheva M, Genova M, Berger MR (2002) Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines. J Cancer Res Clin Oncol 128:271\u2013278","journal-title":"J Cancer Res Clin Oncol"},{"key":"278_CR23","first-page":"1287","volume":"90","author":"S Knop","year":"2005","unstructured":"Knop S, Straka C, Haen M, Schwedes R, Hebart H, Einsele H (2005) The eficiacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 90:1287\u20131288","journal-title":"Haematologica"},{"key":"278_CR48","unstructured":"Leoni L, Bailey B, Reifert J, Niemeyer C, Bendall H, Dauffenbach L, Kerfoot C (2003) SDX-105 (Bendamustine), a clinically active antineoplastic agent possesses a unique mechanism of action. Blood 102(11):534-II"},{"key":"278_CR24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00432-005-0050-z","volume":"132","author":"T Lissitchkov","year":"2006","unstructured":"Lissitchkov T, Arnaudov G, Peytchev D, Merkle Kh (2006) Phase-I\/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 132:99\u2013104","journal-title":"J Cancer Res Clin Oncol"},{"key":"278_CR25","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1101\/gad.14.12.1448","volume":"14","author":"Q Liu","year":"2000","unstructured":"Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K et al (2000) Chk1 is an essential kinase that is regulated by Atr and required for the G2\/M DNA damage checkpoint. Genes Dev 14:1448\u20131459","journal-title":"Genes Dev"},{"key":"278_CR26","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1126\/science.282.5395.1893","volume":"282","author":"S Matsuoka","year":"1998","unstructured":"Matsuoka S, Huang M, Elledge SJ (1998) Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282:1893\u20131897","journal-title":"Science"},{"key":"278_CR27","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1126\/science.288.5470.1425","volume":"288","author":"N Mailand","year":"2000","unstructured":"Mailand N, Falck J, Lukas C, Sylju\u00e5sen RG, Welcker M, Bartek J et al (2000) Rapid destruction of human Cdc25A in response to DNA damage. Science 288:1425\u20131429","journal-title":"Science"},{"key":"278_CR28","first-page":"1647","volume":"13","author":"A Maity","year":"1996","unstructured":"Maity A, Hwang A, Janss A, Phillips P, McKenna WG, Muschel RJ (1996) Delayed cyclin B1 expression during the G2 arrest following DNA damage. Oncogene 13:1647\u20131657","journal-title":"Oncogene"},{"key":"278_CR29","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/sj.onc.1205196","volume":"21","author":"M Miyakoda","year":"2002","unstructured":"Miyakoda M, Suzuki K, Kodama S, Watanabe M (2002) Activation of ATM and phosphorylation of p53 by heat shock. Oncogene 21:1090\u20131096","journal-title":"Oncogene"},{"key":"278_CR30","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1200\/JCO.1998.16.12.3832","volume":"16","author":"Myeloma Trialists\u2019 Collaborative Group","year":"1998","unstructured":"Myeloma Trialists\u2019 Collaborative Group (1998) Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 16:3832\u20133842","journal-title":"J Clin Oncol"},{"key":"278_CR31","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/sj.leu.2404200","volume":"20","author":"TA Navas","year":"2006","unstructured":"Navas TA, Nguyen AN, Hideshima T, Reddy M, Ma JY, Haghnazari E et al (2006) Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo. Leukemia 20:1017\u20131027","journal-title":"Leukemia"},{"key":"278_CR32","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.yexcr.2006.02.026","volume":"312","author":"AN Nguyen","year":"2006","unstructured":"Nguyen AN, Stebbins EG, Henson M, O\u2019Young G, Choi SJ, Quon D et al (2006) Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Exp Cell Res 312:1909\u20131923","journal-title":"Exp Cell Res"},{"key":"278_CR33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/344503a0","volume":"344","author":"P Nurse","year":"1990","unstructured":"Nurse P (1990) Universal control mechanism regulating onset of M-phase. Nature 344:503\u2013508","journal-title":"Nature"},{"key":"278_CR34","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ng1129","volume":"33","author":"M O\u2019Driscoll","year":"2003","unstructured":"O\u2019Driscoll M, Ruiz-Perez VL, Woods CG, Jeggo PA, Goodship JA (2003) A splicing mutation affecting expression of ataxia-telangiectasia and Rad3-related protein (ATR) results in Seckel syndrome. Nat Genet 33:497\u2013501","journal-title":"Nat Genet"},{"key":"278_CR35","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/sj.emboj.7600972","volume":"25","author":"G Pedraza-Alva","year":"2006","unstructured":"Pedraza-Alva G, Koulnis M, Charland C, Thornton T, Clements JL, Schlissel MS et al (2006) Activation of p38 MAP kinase by DNA double-strand breaks in V(D)J recombination induces a G2\/M cell cycle checkpoint. EMBO J 25:763\u2013773","journal-title":"EMBO J"},{"key":"278_CR36","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood-2004-02-0408","volume":"104","author":"A Palumbo","year":"2004","unstructured":"Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M et al (2004) Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 104:3052\u20133057","journal-title":"Blood"},{"key":"278_CR37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00432-005-0074-4","volume":"132","author":"W Ponisch","year":"2006","unstructured":"Ponisch W, Mitrou PS, Merkle K, Herold M, Assmann M, Wilhelm G et al (2006) Treatment of bendamustine and prednisolone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone\u2014a randomised phase 3 study of the East German Study group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 132:205\u2013212","journal-title":"J Cancer Res Clin Oncol"},{"key":"278_CR38","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.277.5331.1497","volume":"277","author":"Y Sanchez","year":"1997","unstructured":"Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, Elledge SJ (1997) Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277:1497\u20131501","journal-title":"Science"},{"key":"278_CR39","first-page":"4375","volume":"59","author":"JN Sarkaria","year":"1999","unstructured":"Sarkaria JN, Busby EC, Tibbets RS, Roos P, Taya Y, Karnitz LM et al (1999) Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 59:4375\u20134382","journal-title":"Cancer Res"},{"key":"278_CR40","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00001813-199606000-00007","volume":"7","author":"D Strumberg","year":"1996","unstructured":"Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S (1996) Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 7:415\u2013421","journal-title":"Anticancer Drugs"},{"key":"278_CR41","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1101\/gad.13.2.152","volume":"13","author":"RS Tibbetts","year":"1999","unstructured":"Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY et al (1999) A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev 13:152\u2013157","journal-title":"Genes Dev"},{"key":"278_CR42","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.1038\/sj.onc.1204665","volume":"20","author":"GA Turenne","year":"2001","unstructured":"Turenne GA, Paul P, Laflair L, Price BD (2001) Activation of p53 transcriptional activity requires ATM\u2019s kinase domain and multiple N-terminal serine residues of p53. Oncogene 20:5100\u20135110","journal-title":"Oncogene"},{"key":"278_CR43","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/01.cad.0000175587.31940.19","volume":"16","author":"G Minckwitz von","year":"2005","unstructured":"von Minckwitz G, Chernozemsky I, Sirakova L, Chilingirov P, Souchon R, Marschner N et al (2005) Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBC. Anticancer Drugs 16:871\u2013877","journal-title":"Anticancer Drugs"},{"key":"278_CR44","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1182\/blood-2005-06-2486","volume":"107","author":"S Wang","year":"2006","unstructured":"Wang S, Yang J, Qian J, Wezeman M, Kwak LW, Yi Q (2006) Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood 107:2432\u20132439","journal-title":"Blood"},{"key":"278_CR45","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.bbrc.2004.04.030","volume":"318","author":"K Yamane","year":"2004","unstructured":"Yamane K, Taylor K, Kinsella TJ (2004) Mismatch repair-mediated G2\/M arrest by 6-thioguanine involves the ATR-Chk1 pathway. Biochem Biophys Res Commun 318:297\u2013302","journal-title":"Biochem Biophys Res Commun"},{"key":"278_CR46","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1158\/1535-7163.1147.3.9","volume":"3","author":"T Yan","year":"2004","unstructured":"Yan T, Desai AB, Jacobberger JW, Sramkoski RM, Loh T, Kinsella TJ (2004) CHK1 and CHK2 are differentially involved in mismatch repair-mediated 6-thioguanine-induced cell cycle checkpoint responses. Mol Cancer Ther 3:1147\u20131157","journal-title":"Mol Cancer Ther"},{"key":"278_CR47","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00432-001-0303-4","volume":"128","author":"K Zulkowski","year":"2002","unstructured":"Zulkowski K, Kath R, Semrau R, Merkle K, Hoffken K (2002) Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine. J Cancer Res Clin Oncol 128:111\u2013113","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-007-0278-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-007-0278-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-007-0278-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,13]],"date-time":"2023-05-13T10:22:37Z","timestamp":1683973357000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-007-0278-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,25]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,12,6]]}},"alternative-id":["278"],"URL":"https:\/\/doi.org\/10.1007\/s00432-007-0278-x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1098766.554894","asserted-by":"object"}]},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,25]]}}}